AM-Pharma Begins Phase 2 Trial of Ilofotase Alfa For Renal Damage Prevention

January 22, 2024

Voranigo Receives FDA Clearance as a Brain Tumor Inhibitor

August 8, 2024

Roche’s $3.5 billion acquisition of 89bio and its phase 3 mdication makes it a MASH player

September 24, 2025

Must Read

AstraZeneca Acquires Remaining China Rights to C-CAR031 in $630 Million Agreement

January 21, 2026

FDA Pushes Back Review Decisions for Four Drugs in National Priority Voucher Program

January 20, 2026

J&J Reports Phase 3 Results Showing Tecvayli Benefit as Monotherapy in Multiple Myeloma

January 20, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Merck Gets $700M Funding From Blackstone For Cancer Therapy R&D

Pfizer to Withdraw Vyndaqel in the U.S. Before Patent Expiration in 2028

Roche Ends Development of Obesity Candidate CT-173 and Discontinues Multiple Early-Stage Programs

$20 Million Pediatric CRISPR Center Launched to Develop Treatments for Rare Genetic Diseases

J&J Reports Phase 3 Results Showing Tecvayli Benefit as Monotherapy in Multiple Myeloma

BMS’ Camzyos Scores Big Trial Win, Expansion to Adolescent Patients Imminent

MetaVia Reports Phase 1 Results for DA-1726 Showing 9.1% Average Weight Loss

Nido closes after phase 2 trial of flagship program unsuccessful

AstraZeneca Acquires Remaining China Rights to C-CAR031 in $630 Million Agreement

AbbVie Licenses Ex-China Rights to RemeGen’s PD-1/VEGF Bispecific RC148 for $650 Million Upfront

Samsung Biologics to Shell Out $280M to Acquire GSK’s U.S. Plant

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

PicnicHealth Launches New Service Bringing Observational Clinical Trials to the Virtual Realm

Reg impact assessment next in GenAI’s sights, experts claim

The now-urgent automation agenda: out-of-control regulatory workloads necessitate AI adoption

Improving life science R&D outcomes with AI

The medical device sector’s surging regulatory burden: how are suppliers coping?

Tag: China rights acquisition

AstraZeneca Acquires Remaining China Rights to C-CAR031 in $630 Million Agreement

Editor Picks

AM-Pharma Begins Phase 2 Trial of Ilofotase Alfa For Renal Damage Prevention

Voranigo Receives FDA Clearance as a Brain Tumor Inhibitor

Roche’s $3.5 billion acquisition of 89bio and its phase 3 mdication makes it a MASH player

Must Read

AstraZeneca Acquires Remaining China Rights to C-CAR031 in $630 Million Agreement

FDA Pushes Back Review Decisions for Four Drugs in National Priority Voucher Program

J&J Reports Phase 3 Results Showing Tecvayli Benefit as Monotherapy in Multiple Myeloma

Hot Topics

About Us

Follow Us